JP2019500349A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500349A5 JP2019500349A5 JP2018529257A JP2018529257A JP2019500349A5 JP 2019500349 A5 JP2019500349 A5 JP 2019500349A5 JP 2018529257 A JP2018529257 A JP 2018529257A JP 2018529257 A JP2018529257 A JP 2018529257A JP 2019500349 A5 JP2019500349 A5 JP 2019500349A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- stxbp1
- mrna
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004999 messenger RNA Proteins 0.000 claims description 107
- 108090000623 proteins and genes Proteins 0.000 claims description 97
- 102000004169 proteins and genes Human genes 0.000 claims description 86
- 238000000034 method Methods 0.000 claims description 68
- 230000000717 retained effect Effects 0.000 claims description 64
- 230000000692 anti-sense effect Effects 0.000 claims description 61
- 101000648077 Homo sapiens Syntaxin-binding protein 1 Proteins 0.000 claims description 60
- 102100025293 Syntaxin-binding protein 1 Human genes 0.000 claims description 60
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- 108020005067 RNA Splice Sites Proteins 0.000 claims description 30
- 108700028369 Alleles Proteins 0.000 claims description 28
- 230000002950 deficient Effects 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 6
- 238000010255 intramuscular injection Methods 0.000 claims description 5
- 238000007913 intrathecal administration Methods 0.000 claims description 5
- 238000010253 intravenous injection Methods 0.000 claims description 5
- 238000007914 intraventricular administration Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000010254 subcutaneous injection Methods 0.000 claims description 5
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 4
- 230000007812 deficiency Effects 0.000 claims description 4
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 claims description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 4
- 208000030264 developmental and epileptic encephalopathy 4 Diseases 0.000 claims description 2
- 208000019152 developmental and epileptic encephalopathy, 4 Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 208000002761 neurofibromatosis 2 Diseases 0.000 description 45
- 208000022032 neurofibromatosis type 2 Diseases 0.000 description 45
- 201000000788 Niemann-Pick disease type C1 Diseases 0.000 description 41
- 239000000203 mixture Substances 0.000 description 41
- 102100022146 Arylsulfatase A Human genes 0.000 description 40
- 101000901140 Homo sapiens Arylsulfatase A Proteins 0.000 description 40
- 101001099372 Homo sapiens Peroxisome biogenesis factor 1 Proteins 0.000 description 40
- 101001088739 Homo sapiens Probable inactive ribonuclease-like protein 12 Proteins 0.000 description 40
- 101001099922 Homo sapiens Retinoic acid-induced protein 1 Proteins 0.000 description 40
- 101000925985 Homo sapiens Translation initiation factor eIF-2B subunit epsilon Proteins 0.000 description 40
- 102100038881 Peroxisome biogenesis factor 1 Human genes 0.000 description 40
- 102100033988 Probable inactive ribonuclease-like protein 12 Human genes 0.000 description 40
- 102100034267 Translation initiation factor eIF-2B subunit epsilon Human genes 0.000 description 40
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 39
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 39
- 102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 description 39
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 description 39
- 101001124388 Homo sapiens NPC intracellular cholesterol transporter 1 Proteins 0.000 description 39
- 101000976959 Homo sapiens Transcription factor 4 Proteins 0.000 description 39
- 101000596771 Homo sapiens Transcription factor 7-like 2 Proteins 0.000 description 39
- 101001057681 Homo sapiens Translation initiation factor eIF-2B subunit beta Proteins 0.000 description 39
- 102100029565 NPC intracellular cholesterol transporter 1 Human genes 0.000 description 39
- 102100023489 Transcription factor 4 Human genes 0.000 description 39
- 102100027065 Translation initiation factor eIF-2B subunit beta Human genes 0.000 description 39
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 38
- 102000014817 CACNA1A Human genes 0.000 description 37
- 101000954986 Homo sapiens Merlin Proteins 0.000 description 37
- 101000935117 Homo sapiens Voltage-dependent P/Q-type calcium channel subunit alpha-1A Proteins 0.000 description 37
- 102100037106 Merlin Human genes 0.000 description 37
- 102100027711 Histone-lysine N-methyltransferase SETD5 Human genes 0.000 description 36
- 101000650669 Homo sapiens Histone-lysine N-methyltransferase SETD5 Proteins 0.000 description 36
- 101000753197 Homo sapiens Sodium/potassium-transporting ATPase subunit alpha-2 Proteins 0.000 description 36
- 102100030681 SH3 and multiple ankyrin repeat domains protein 3 Human genes 0.000 description 36
- 101710101741 SH3 and multiple ankyrin repeat domains protein 3 Proteins 0.000 description 36
- 102100021955 Sodium/potassium-transporting ATPase subunit alpha-2 Human genes 0.000 description 36
- 101000577696 Homo sapiens Proline-rich transmembrane protein 2 Proteins 0.000 description 34
- 102100028840 Proline-rich transmembrane protein 2 Human genes 0.000 description 34
- 108010082945 Eukaryotic Initiation Factor-2B Proteins 0.000 description 28
- 102100027059 Translation initiation factor eIF-2B subunit alpha Human genes 0.000 description 28
- 101000585079 Homo sapiens Syntaxin-1B Proteins 0.000 description 22
- 102100029931 Syntaxin-1B Human genes 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 22
- 208000011580 syndromic disease Diseases 0.000 description 22
- 101000575454 Homo sapiens Major facilitator superfamily domain-containing protein 8 Proteins 0.000 description 18
- 102100025613 Major facilitator superfamily domain-containing protein 8 Human genes 0.000 description 18
- -1 PRICCKLE2 Proteins 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 102100035028 Alpha-L-iduronidase Human genes 0.000 description 14
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 description 14
- 101000742006 Homo sapiens Prickle-like protein 2 Proteins 0.000 description 13
- 102100038629 Prickle-like protein 2 Human genes 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 108091092195 Intron Proteins 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000001314 paroxysmal effect Effects 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 208000014060 Niemann-Pick disease Diseases 0.000 description 6
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 6
- 230000001037 epileptic effect Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 5
- 206010003591 Ataxia Diseases 0.000 description 4
- 208000012661 Dyskinesia Diseases 0.000 description 4
- 208000002091 Febrile Seizures Diseases 0.000 description 4
- 208000025270 Heimler syndrome 1 Diseases 0.000 description 4
- 208000034800 Leukoencephalopathies Diseases 0.000 description 4
- 108091027974 Mature messenger RNA Proteins 0.000 description 4
- 208000036626 Mental retardation Diseases 0.000 description 4
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 4
- 208000000060 Migraine with aura Diseases 0.000 description 4
- 108010085839 Neurofibromin 2 Proteins 0.000 description 4
- 102000007517 Neurofibromin 2 Human genes 0.000 description 4
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 4
- 201000006797 autosomal dominant nonsyndromic deafness Diseases 0.000 description 4
- 201000003452 benign familial neonatal epilepsy Diseases 0.000 description 4
- 201000010295 benign neonatal seizures Diseases 0.000 description 4
- 231100000895 deafness Toxicity 0.000 description 4
- 208000031362 familial hemiplegic 2 migraine Diseases 0.000 description 4
- 206010067039 familial hemiplegic migraine Diseases 0.000 description 4
- 208000013778 familial hemiplegic migraine 2 Diseases 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 206010027191 meningioma Diseases 0.000 description 4
- 201000003631 narcolepsy Diseases 0.000 description 4
- 201000000417 schizophrenia 15 Diseases 0.000 description 4
- 208000012581 schwannomatosis 1 Diseases 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 210000004885 white matter Anatomy 0.000 description 4
- 208000005875 Alternating hemiplegia of childhood Diseases 0.000 description 3
- 208000009017 Athetosis Diseases 0.000 description 3
- 208000008882 Benign Neonatal Epilepsy Diseases 0.000 description 3
- 206010067866 Benign familial neonatal convulsions Diseases 0.000 description 3
- 206010008748 Chorea Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000012601 choreatic disease Diseases 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 206010016284 febrile convulsion Diseases 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 230000000858 peroxisomal effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 101150072179 ATP1 gene Proteins 0.000 description 2
- 101100003366 Arabidopsis thaliana ATPA gene Proteins 0.000 description 2
- 108010078286 Ataxins Proteins 0.000 description 2
- 102000014461 Ataxins Human genes 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 101100329759 Ceratitis capitata CTXA1 gene Proteins 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- 102100021649 Elongator complex protein 6 Human genes 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 101100065219 Homo sapiens ELP6 gene Proteins 0.000 description 2
- 208000002033 Myoclonus Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 208000033063 Progressive myoclonic epilepsy Diseases 0.000 description 2
- 201000003620 Spinocerebellar ataxia type 6 Diseases 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 101150105046 atpI gene Proteins 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 201000001204 progressive myoclonus epilepsy Diseases 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 102100029231 Alpha-2,8-sialyltransferase 8B Human genes 0.000 description 1
- 101710105328 Alpha-2,8-sialyltransferase 8B Proteins 0.000 description 1
- 102100024400 Diphthine methyltransferase Human genes 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000030586 Hereditary sensory neuropathy-deafness-dementia syndrome Diseases 0.000 description 1
- 102100029768 Histone-lysine N-methyltransferase SETD1A Human genes 0.000 description 1
- 101001053233 Homo sapiens Diphthine methyltransferase Proteins 0.000 description 1
- 101000865038 Homo sapiens Histone-lysine N-methyltransferase SETD1A Proteins 0.000 description 1
- 101000760764 Homo sapiens Tyrosyl-DNA phosphodiesterase 1 Proteins 0.000 description 1
- 206010065657 Paroxysmal choreoathetosis Diseases 0.000 description 1
- 101100255666 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RTR2 gene Proteins 0.000 description 1
- 206010040037 Sensory neuropathy hereditary Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 102000002027 Tuberin Human genes 0.000 description 1
- 108050009309 Tuberin Proteins 0.000 description 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 description 1
- 102100024579 Tyrosyl-DNA phosphodiesterase 1 Human genes 0.000 description 1
- 208000011916 alternating hemiplegia Diseases 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 description 1
- 201000006847 hereditary sensory neuropathy Diseases 0.000 description 1
- 201000000919 hereditary sensory neuropathy type 1E Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 208000013667 paroxysmal dyskinesia Diseases 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- SZCZSKMCTGEJKI-UHFFFAOYSA-N tuberin Natural products COC1=CC=C(C=CNC=O)C=C1 SZCZSKMCTGEJKI-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022013867A JP2022062141A (ja) | 2015-12-14 | 2022-02-01 | 中枢神経系疾患の処置のための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267256P | 2015-12-14 | 2015-12-14 | |
| US62/267,256 | 2015-12-14 | ||
| US201662319011P | 2016-04-06 | 2016-04-06 | |
| US62/319,011 | 2016-04-06 | ||
| PCT/US2016/066721 WO2017106382A1 (en) | 2015-12-14 | 2016-12-14 | Compositions and methods for treatment of central nervous system diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022013867A Division JP2022062141A (ja) | 2015-12-14 | 2022-02-01 | 中枢神経系疾患の処置のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500349A JP2019500349A (ja) | 2019-01-10 |
| JP2019500349A5 true JP2019500349A5 (enExample) | 2020-01-30 |
| JP7049249B2 JP7049249B2 (ja) | 2022-04-06 |
Family
ID=59057524
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529257A Active JP7049249B2 (ja) | 2015-12-14 | 2016-12-14 | 中枢神経系疾患の処置のための組成物および方法 |
| JP2022013867A Pending JP2022062141A (ja) | 2015-12-14 | 2022-02-01 | 中枢神経系疾患の処置のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022013867A Pending JP2022062141A (ja) | 2015-12-14 | 2022-02-01 | 中枢神経系疾患の処置のための組成物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| EP (2) | EP3389725B1 (enExample) |
| JP (2) | JP7049249B2 (enExample) |
| CA (1) | CA3005246A1 (enExample) |
| WO (1) | WO2017106382A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| EP3201339A4 (en) | 2014-10-03 | 2018-09-19 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| EP3359685A1 (en) | 2015-10-09 | 2018-08-15 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
| KR102604132B1 (ko) | 2015-12-14 | 2023-11-17 | 콜드스프링하버러보러토리 | 상염색체 우성 정신 지체 5 및 드라베 증후군의 치료를 위한 안티센스 올리고머 |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| CA3005131A1 (en) * | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of tuberous sclerosis complex |
| KR102712656B1 (ko) | 2017-01-23 | 2024-10-04 | 리제너론 파마슈티칼스 인코포레이티드 | Hsd17b13 변종 및 이것의 용도 |
| US11479802B2 (en) | 2017-04-11 | 2022-10-25 | Regeneron Pharmaceuticals, Inc. | Assays for screening activity of modulators of members of the hydroxy steroid (17-beta) dehydrogenase (HSD17B) family |
| SI3673080T1 (sl) | 2017-08-25 | 2024-03-29 | Stoke Therapeutics, Inc. | Protismiselni oligomeri za zdravljenje bolezenskih stanj in bolezni |
| EP3461837A1 (en) * | 2017-09-28 | 2019-04-03 | Secarna Pharmaceuticals GmbH & Co. KG | Inhibitor inhibiting the expression of pprx1 |
| AU2018348195B2 (en) | 2017-10-11 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation |
| HRP20250322T1 (hr) * | 2017-10-23 | 2025-06-06 | Stoke Therapeutics, Inc. | Protusmisleni oligomeri, namijenjeni liječenju stanja i bolesti uzrokovanih raspadanjem rna posredovanim besmislenim mutacijama |
| BR112020018758A2 (pt) | 2018-03-21 | 2021-01-26 | Regeneron Pharmaceuticals, Inc. | agente de ácido ribonucleico de fita dupla, célula, vetor, composição farmacêutica, e, métodos para inibição da expressão de 17¿-hidroxiesteroide desidrogenases tipo 13, para tratamento de um indivíduo, para prevenção de um sintoma em um indivíduo, para redução do risco de desenvolver doença hepática crônica, para inibição da progressão de esteatose, para inibição do acúmulo de gotículas de lipídios |
| BR112020022512A2 (pt) | 2018-05-04 | 2021-05-04 | Stoke Therapeutics, Inc. | métodos e composições para tratamento de doença de armazenamento de éster de colesteril |
| CA3110211A1 (en) | 2018-08-20 | 2020-02-27 | Rogcon, Inc. | Antisense oligonucleotides targeting scn2a for the treatment of scn1a encephalopathies |
| EP3942049A4 (en) | 2019-03-20 | 2023-10-18 | President And Fellows Of Harvard College | ANTISENSE OLIGONUCLEOTIDE BASED PROGRANULIN AUGMENTATION THERAPY FOR NEURODEGENERATIVE DISEASES |
| US20220228146A1 (en) * | 2019-05-06 | 2022-07-21 | The Children's Hospital Of Philadelphia | Micro-rna site blocking oligonucleotides for the treatment of epileptic encephalopathy and neurodevelopmental disorders |
| JP2022531809A (ja) * | 2019-05-14 | 2022-07-11 | デューク ユニバーシティ | ＡＴＰａｓｅ媒介性疾患の処置のための組成物および方法 |
| US20220333110A1 (en) * | 2019-09-30 | 2022-10-20 | The University Of Tokyo | Nucleic acid that inhibits expression of mex3b gene, mex3b gene expression inhibiting agent, method for inhibiting mex3b gene expression, and prophylactic or therapeutic agent for disease caused by mex3b gene expression |
| JP2023524671A (ja) * | 2020-04-27 | 2023-06-13 | ウニベルジテート ウルム | Ｓｈａｎｋ３の発現を増加させるアンチセンスオリゴヌクレオチド |
| AU2021270720A1 (en) | 2020-05-11 | 2022-12-08 | Stoke Therapeutics, Inc. | OPA1 antisense oligomers for treatment of conditions and diseases |
| US20240392297A1 (en) * | 2020-12-23 | 2024-11-28 | Eli Lilly And Company | Rna therapeutics and methods of use thereof |
| IL307167A (en) * | 2021-04-05 | 2023-11-01 | Itayandbiond Ltd | Small activating RNA that increases expression of SHANK and a method for treating intellectual disabilities and associated diseases associated with SHANK haploinsufficiency |
| CN118434858A (zh) * | 2021-12-07 | 2024-08-02 | 豪夫迈·罗氏有限公司 | 靶向actl6b的反义寡核苷酸 |
| CN118647405A (zh) * | 2022-01-25 | 2024-09-13 | 上海魁特迪生物科技有限公司 | 改善认知障碍的方法 |
| WO2023168427A1 (en) | 2022-03-03 | 2023-09-07 | Yale University | Compositions and methods for delivering therapeutic polynucleotides for exon skipping |
| CN114836532A (zh) * | 2022-04-28 | 2022-08-02 | 福建医科大学附属第一医院 | Eif2b5基因突变作为靶标在诊断消融性白质脑病中的应用 |
| WO2024126654A1 (en) * | 2022-12-14 | 2024-06-20 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides targeting actl6b |
| WO2024226471A2 (en) * | 2023-04-24 | 2024-10-31 | Biomarin Pharmaceutical Inc. | Compositions and methods for treating stxbp1 disorders |
| WO2025038842A1 (en) * | 2023-08-15 | 2025-02-20 | The Children's Medical Center Corporation | Systems and methods for modifying a polynucleotide |
| CN117122688B (zh) * | 2023-08-31 | 2024-06-04 | 中国科学院脑科学与智能技术卓越创新中心 | 作用于前脑兴奋性神经元的prrt2及其上调剂的应用 |
| WO2025217494A1 (en) * | 2024-04-11 | 2025-10-16 | The University Of Chicago | Splice-switching oligonucleotides for treating cacna1a-associated disorders |
| WO2025250031A1 (en) * | 2024-05-31 | 2025-12-04 | Bial - Portela & Ca., S.A. | Antisense oligonucleotides for treatment of stxbp1-related developmental epileptic encephalopathy |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4866042A (en) | 1987-11-18 | 1989-09-12 | Neuwelt Edward A | Method for the delivery of genetic material across the blood brain barrier |
| US6294520B1 (en) | 1989-03-27 | 2001-09-25 | Albert T. Naito | Material for passage through the blood-brain barrier |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| FI951404A7 (fi) | 1992-09-25 | 1995-03-24 | Rhone Poulenc Rorer Sa | Adenovirusvektoreita vieraiden geenien siirtämiseksi keskushermostojärjestelmän , erityisesti aivojen, soluihin |
| US5656612A (en) | 1994-05-31 | 1997-08-12 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| FR2727867B1 (fr) | 1994-12-13 | 1997-01-31 | Rhone Poulenc Rorer Sa | Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux |
| US6936589B2 (en) | 2001-09-28 | 2005-08-30 | Albert T. Naito | Parenteral delivery systems |
| WO2007047913A2 (en) | 2005-10-20 | 2007-04-26 | Isis Pharmaceuticals, Inc | Compositions and methods for modulation of lmna expression |
| EP3705125B1 (en) | 2007-12-04 | 2023-07-05 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| JP5608863B2 (ja) * | 2007-12-28 | 2014-10-15 | 公立大学法人横浜市立大学 | 新生児期〜乳児期発症の難治性てんかんの検出方法 |
| SI3449926T1 (sl) | 2009-06-17 | 2020-04-30 | Biogen Ma Inc. | Sestave in metode za modulacijo združevanja SMN2 pri subjektu |
| US20140128449A1 (en) | 2011-04-07 | 2014-05-08 | The Board Of Regents Of The University Of Texas System | Oligonucleotide modulation of splicing |
| WO2012178122A2 (en) * | 2011-06-23 | 2012-12-27 | Cold Spring Harbor Laboratory | Phenocopy model of disease |
| EP3248982A1 (en) | 2011-07-19 | 2017-11-29 | Wave Life Sciences Ltd. | Thiosulfonate reagents for the synthesis of functionalized nucleic acids |
| CA2930859C (en) | 2013-09-04 | 2022-05-03 | Cold Spring Harbor Laboratory | Reducing nonsense-mediated mrna decay |
-
2016
- 2016-12-14 JP JP2018529257A patent/JP7049249B2/ja active Active
- 2016-12-14 WO PCT/US2016/066721 patent/WO2017106382A1/en not_active Ceased
- 2016-12-14 CA CA3005246A patent/CA3005246A1/en active Pending
- 2016-12-14 EP EP16876621.0A patent/EP3389725B1/en active Active
- 2016-12-14 EP EP22166699.3A patent/EP4104867A3/en not_active Withdrawn
-
2022
- 2022-02-01 JP JP2022013867A patent/JP2022062141A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019500349A5 (enExample) | ||
| JP7420679B2 (ja) | 状態および疾患の処置のためのアンチセンスオリゴマー | |
| JP2019501892A5 (enExample) | ||
| US20250270563A1 (en) | Targeted augmentation of nuclear gene output | |
| JP2018538288A5 (enExample) | ||
| JP2022062140A5 (enExample) | ||
| JP2019500346A5 (enExample) | ||
| CA2803882C (en) | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna | |
| JP2019500350A5 (enExample) | ||
| JP2019500347A5 (enExample) | ||
| CA2795145C (en) | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 | |
| JP2018538287A5 (enExample) | ||
| US20190040394A1 (en) | Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf | |
| US20170037411A1 (en) | Modulation of pre-mrna using splice modulating oligonucleotides as therapeutic agents in the treatment of disease | |
| US20160138023A1 (en) | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf | |
| JP2019500345A5 (enExample) | ||
| US20220265864A1 (en) | Splice modulating oligonucleotides targeting receptor for advanced glycation end products and methods of use | |
| US20210246454A1 (en) | Splice modulating oligonucleotides targeting receptor for advanced glycation end products and methods of use | |
| CN102844435A (zh) | 通过抑制吡咯啉-5-羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病 | |
| CN116209761A (zh) | 靶向rna结合蛋白位点的寡核苷酸 | |
| CN107532169B (zh) | 用于治疗杜兴氏肌肉营养不良症的发动蛋白2抑制剂 | |
| US20200407721A1 (en) | Compounds of chemically modified oligonucleotides and methods of use thereof | |
| JP2024524974A (ja) | ナンセンス変異依存ｒｎａ分解機構に基づく病態及び疾患の処置のためのアンチセンスオリゴマー | |
| CA3099280A1 (en) | Methods and compositions for treatment of cholesteryl ester storage disease | |
| JPWO2019213525A5 (enExample) |